Starpharma

Shares of nanotech company
Starpharma Holdings
have gained more than 30 per cent this year, easily outperforming the broader market. The company is involved in the development and commercialisation of dendrimer products for the life sciences and pharmaceutical industries, and is developing a gel to prevent sexually transmitted infections. It counts fund managers Acorn Capital and Orbis Investment Management among its major shareholders, with US behemoth Dow Chemical Company another backer, holding an 8 .6 per stake. Late last year, Southern Cross Equities and Shaw Stockbroking both recommended Starpharma stock to clients.